Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

@article{Kruis2001LowDB,
  title={Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses},
  author={W. Kruis and S. Schreiber and D. Theuer and J. Brandes and E. Sch{\"u}tz and S. Howaldt and B. Krakamp and J. H{\"a}mling and H. M{\"o}nnikes and I. Koop and M. Stolte and D. Pallant and U. Ewald},
  journal={Gut},
  year={2001},
  volume={49},
  pages={783 - 789}
}
  • W. Kruis, S. Schreiber, +10 authors U. Ewald
  • Published 2001
  • Medicine
  • Gut
  • BACKGROUND Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug. Its efficacy in comparison with standard mesalazine therapy and the optimum dose for maintaining remission of ulcerative colitis are still unclear. AIMS To compare the relapse preventing effect and safety profile of two doses of balsalazide and a standard dose of Eudragit coated mesalazine. METHODS A total of 133 patients with ulcerative colitis in remission were recruited to participate in a double blind… CONTINUE READING

    Paper Mentions

    BLOG POST
    Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    • 23
    • Highly Influenced
    Balsalazide in treating colonic diseases
    • 2

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 29 REFERENCES